Orbimed Advisors Trims $125 After Breakout Year in Biotech
A major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
Understand portfolio volatility for bonds versus index funds in retirement and how it affects withdrawal strategies and peace of mind.
23,614 articlesA major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
A hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Can a $5,000 investment unlock big potential in quantum computing stocks? This guide breaks down the landscape, insid...
A major fund trimmed its stake in a biotech ahead of a June FDA milestone. This article explains what that means for ...
As GLP-1 therapies reshape obesity treatment, investors eye the best weight loss drug stock bets for 2026. This guide...
Is SpaceX heading to the stock market? This article breaks down the IPO question with insights inspired by Jim Cramer...
A potential agreement with Iran could unlock sanctions relief, release frozen assets, and reopen Gulf shipping. Negot...
A niche nuclear tech stock reported solid revenue gains, but a large fund reduced its holdings. Learn how to read the...
Investors eye the long end of the curve as Kevin Warsh's QT stance shifts income dynamics. Forget utility dividends. ...
SpaceX's S-1 filing exposes Bitcoin exposure and a broader digital-asset playbook, signaling a new price benchmark fo...
May delivered a sharp reversal for Bitcoin ETFs, with the biggest weekly outflows since January as risk-off trading s...
A Hong Kong based fund recently exited its stake in a leading China logistics platform for about $194 million. This a...